ARG1 Inhibition after Neonatal Hypoxic-Ischemic Brain Injury

Area of Science:

• Neuroscience
• Immunology
• Developmental Biology

Background:

• Neonatal hypoxic-ischemic (HI) brain injury causes significant mortality and disability.
• Effective neuroprotective strategies are limited.
• Microglia, particularly arginase-1 (ARG1) expressing cells, play key roles in HI injury and repair, but their function in tissue remodeling is unclear.

Purpose of the Study:

• To investigate the role of ARG1⁺ microglia in neonatal HI brain injury.
• To determine the impact of ARG1 inhibition on microglial function and brain repair.

Main Methods:

• Neonatal mice underwent HI (Vannucci procedure).
• Pharmacological inhibition of ARG1 activity using Nor-NOHA.
• Assessment of ARG1 expression, microglial morphology, efferocytosis, scar formation, and injury volume via immunohistochemistry, Western blotting, and enzyme assays.

Main Results:

• ARG1⁺ microglia demonstrated phagocytic activity towards apoptotic neurons.
• ARG1 inhibition impaired microglial efferocytosis and increased brain injury volume.
• ARG1⁺ microglia were involved in extracellular matrix (ECM) deposition, indicated by co-localization with collagen I alpha 1 (Col1a1).
• Inhibition of ARG1 reduced Col1a1 expression, impacting tissue remodeling.

Conclusions:

• ARG1⁺ microglia are essential for neonatal HI brain injury repair, mediating efferocytosis and ECM remodeling.
• Pharmacological inhibition of ARG1 exacerbates HI brain injury, confirming its reparative function.
• ARG1 is a critical regulator of microglial neuroprotection and a potential therapeutic target for neonatal HI brain injury.